ProShare Advisors
RVNC

ProShare Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

ProShare Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-75,252
Closed -$229K – 2283
2024
Q4 		$229K Buy
75,252
+12,155
+19% +$52.9K ﹤0.01% 1820
2024
Q3 		$327K Buy
63,097
+44,940
+248% +$223K ﹤0.01% 1407
2024
Q2 		$46.7K Sell
18,157
-3,747
-17% -$12.8K ﹤0.01% 1760
2024
Q1 		$108K Buy
21,904
+1,809
+9% +$10.7K ﹤0.01% 1810
2023
Q4 		$177K Buy
20,095
+3,509
+21% +$28.7K ﹤0.01% 1670
2023
Q3 		$190K Buy
16,586
+298
+2% +$5.73K ﹤0.01% 1487
2023
Q2 		$412K Buy
16,288
+1,045
+7% +$32.6K ﹤0.01% 1065
2023
Q1 		$491K Sell
15,243
-1,950
-11% -$60.8K ﹤0.01% 916
2022
Q4 		$317K Buy
17,193
+3,136
+22% +$71.7K ﹤0.01% 1205
2022
Q3 		$379K Buy
14,057
+516
+4% +$10.5K ﹤0.01% 1023
2022
Q2 		$187K Sell
13,541
-7,015
-34% -$108K ﹤0.01% 1493
2022
Q1 		$400K Sell
20,556
-4,869
-19% -$73.8K ﹤0.01% 1441
2021
Q4 		$414K Buy
25,425
+1,085
+4% +$18.1K ﹤0.01% 1586
2021
Q3 		$678K Sell
24,340
-6,722
-22% -$192K ﹤0.01% 1049
2021
Q2 		$921K Buy
31,062
+4,385
+16% +$126K ﹤0.01% 1085
2021
Q1 		$746K Buy
26,677
+2,467
+10% +$68.2K ﹤0.01% 1173
2020
Q4 		$686K Buy
24,210
+5,872
+32% +$152K ﹤0.01% 1076
2020
Q3 		$461K Buy
18,338
+1,504
+9% +$39.4K ﹤0.01% 980
2020
Q2 		$411K Buy
16,834
+6,712
+66% +$132K ﹤0.01% 1053
2020
Q1 		$150K Sell
10,122
-5,751
-36% -$119K ﹤0.01% 1038
2019
Q4 		$258K Sell
15,873
-1,081
-6% -$16.8K ﹤0.01% 1435
2019
Q3 		$220K Buy
16,954
+59
+0.3% +$722 ﹤0.01% 1393
2019
Q2 		$219K Sell
16,895
-2,219
-12% -$28K ﹤0.01% 1389
2019
Q1 		$301K Buy
19,114
+3,120
+20% +$54.1K ﹤0.01% 1258
2018
Q4 		$322K Sell
15,994
-3,084
-16% -$68K ﹤0.01% 1114
2018
Q3 		$474K Sell
19,078
-703
-4% -$19.1K ﹤0.01% 1132
2018
Q2 		$543K Sell
19,781
-526
-3% -$15.8K ﹤0.01% 1072
2018
Q1 		$625K Buy
20,307
+238
+1% +$7.66K ﹤0.01% 1016
2017
Q4 		$717K Buy
20,069
+1,171
+6% +$33.6K 0.01% 974
2017
Q3 		$521K Buy
18,898
+1,377
+8% +$33.4K ﹤0.01% 947
2017
Q2 		$463K Sell
17,521
-482
-3% -$10.7K ﹤0.01% 986
2017
Q1 		$374K Sell
18,003
-4,121
-19% -$84.6K ﹤0.01% 1133
2016
Q4 		$458K Buy
22,124
+2,139
+11% +$35.8K 0.01% 1122
2016
Q3 		$324K Sell
19,985
-3,703
-16% -$53.8K ﹤0.01% 1118
2016
Q2 		$322K Buy
23,688
+670
+3% +$11.8K ﹤0.01% 1173
2016
Q1 		$402K Sell
23,018
-2,218
-9% -$45.1K 0.01% 1088
2015
Q4 		$862K Buy
25,236
+5,474
+28% +$190K 0.01% 808
2015
Q3 		$588K Sell
19,762
-1,344
-6% -$40.8K 0.01% 880
2015
Q2 		$675K Buy
21,106
+331
+2% +$8.51K 0.01% 963
2015
Q1 		$431K Buy
20,775
+3,231
+18% +$55.8K 0.01% 1259
2014
Q4 		$297K Buy
+17,544
New +$306K ﹤0.01% 1517

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ProShare Advisors's RVNC Position: Q1 2025 in Review

ProShare Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 75,252 shares — an estimated $229K sold.

ProShare Advisors first reported a position in RVNC in Q4 2014 and held it in 41 quarters. The position peaked at $921K in Q2 2021. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • ProShare Advisors reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • ProShare Advisors sold 75,252 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $229K.
  • ProShare Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2014 and held it in 41 quarters.
  • ProShare Advisors's Revance Therapeutics, Inc. position peaked at $921K in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on ProShare Advisors's 13F filing for Q1 2025, filed 8 May 2025.